NASDAQ:VRTX Vertex Pharmaceuticals Q3 2026 Earnings Report $503.02 -1.71 (-0.34%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vertex Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $4.76Beat/MissN/AOne Year Ago EPSN/AVertex Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$3.41 billionBeat/MissN/AYoY Revenue GrowthN/AVertex Pharmaceuticals Announcement DetailsQuarterQ3 2026Date11/2/2026TimeAfter Market ClosesConference Call DateMonday, November 2, 2026Conference Call Time7:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Vertex Pharmaceuticals Earnings HeadlinesVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know2 hours ago | finance.yahoo.comAmgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?October 4 at 10:14 AM | fool.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 5 at 1:00 AM | Weiss Ratings (Ad)Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Crosses Above 200 Day Moving Average - Here's WhyOctober 3 at 2:01 AM | americanbankingnews.comVertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different BetsOctober 2 at 11:06 PM | finance.yahoo.comCRISPR Therapeutics to Present Phase 1 Data on Zugo-cel in Refractory Systemic Sclerosis at ACR Convergence 2026October 2 at 10:30 AM | quiverquant.comQSee More Vertex Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vertex Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vertex Pharmaceuticals and other key companies, straight to your email. Email Address About Vertex PharmaceuticalsVertex Pharmaceuticals (NASDAQ:VRTX) is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in molecular biology, genetics and drug discovery to address conditions with significant unmet medical needs. Vertex is best known for its portfolio of cystic fibrosis treatments, including Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis by addressing defects in the CFTR protein. The company serves patients and healthcare providers in the United States and international markets through regulatory approvals and commercial operations across multiple regions. Vertex also commercializes Casgevy, a gene-editing therapy developed with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia. In addition, the company markets Journavx, a non-opioid treatment for acute pain, and is advancing research programs in areas including type 1 diabetes, kidney disease and other serious conditions. Reshma Kewalramani has served as Vertex’s president and chief executive officer since 2017.View Vertex Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
